Genetics of cerebral hemorrhage and microbleeds

Panminerva Medica

Volumn 55, Issue 1, 2013, Pages 11-28

  Lanfranconi, S ^a   Franco, G ^a   Borellini, L ^a   Denaro, F ^b   Basilico, P ^a   Parati, E ^c   Micieli, G ^b   Bersano, A ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Cerebral hemorrhage; Genetic; Genetics; Polymorphism

Indexed keywords

ANIMAL; ARTICLE; BRAIN HEMORRHAGE; GENETIC PREDISPOSITION; GENETICS; HUMAN; METHODOLOGY; NEUROIMAGING; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR;

ANIMALS; CEREBRAL HEMORRHAGE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEUROIMAGING; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84878697541     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (140)

1. The Acute Management of Intracerebral Hemorrhage: A Clinical Review. Anesth Analg 2010;5:1419-27.
2. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009;8:355-69.
3. Liebeskind DS. Imaging the future of stroke: II. Hemorrhage. Ann Neurol 2010;68:581-92.
4. Alberts MJ, McCarron MO, Hoffmann KL, Graffagnino C. Familial clustering of intracerebral hemorrhage: A prospective study in North Carolina. Neurepidemiology 2002;21:18-21.
5. Viswanathan A, Greenberg SM. Chapter 38: Intracerebral hemorrhage. Handb Clin Neurol 2008;93:767-90.
6. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 1987;18:311-24.
7. Qureshi AL, Suri MF, Ostrow PT, Kim SH, Ali Z, Shatla AA et al. Apoptosis as a form of cell death in intracerebral hemorrhage. Neurosurgery 2003;52:1041-7.
8. Qureshi AL, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med 2001;344:1450-60.
9. Qureshi AI, Ali Z, Suri MF, Shuaib A, Baker G, Todd K et al. Extracellular glutamate and other amino acids in experimental intracerebral hemorrhage: an in vivo microdialysis study. Crit Care Med 2003;31:1482-9.
10. Nakamura T, Xi G, Park JW, Hua Y, Ho HJT, Keep RF. Holo-transferrin and thrombin can interact to cause brain damage. Stroke 2005;36:348-52.
11. Wagner KR, Packard BA, Hall CL, Smulian AG, Linke MJ, De Courten-Myers GM et al. Protein oxidation and heme oxygenase-1 induction in porcine white matter following intracerebral infusions of whole blood or plasma. Dev Neurosci 2002;24:154-60.
12. Wang J, Tsirka SE. Tuftsin fragment 1-3 is beneficial when delivered after the induction of intracerebral hemorrhage. Stroke 2005;36:613-48.
13. Alvarez-Sabin J, Delgado P, Abilleira S, Molina CA, Arenillas J, Ribó M et al. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke 2004;35:1316-22.
14. Yang S, Nakamura T, Hua Y, Keep RF, Younger JG, Hoff JT, Xi G. ICH in complement C3-deficient mice. Acta Neurochir Suppl 2006;96:227-31.
15. Fujii Y, Takeuchi S, Harada A, Abe H, Sasaki O, Tanaka R. Hemostatic activation in spontaneous intracerebral hemorrhage. Stroke 2001;32:883-90.
16. Broderick JP, Diringer MN, Hill MD, Brun NC, Mayer SA, Steiner T et al. Recombinant activated factor VII ICH trialnvestigators. Determinants of ICH growth: an exploratory analysis. Stroke 2007;38:1072-5.
17. Gebel JM Jr, Jauch EC, Brott TG, Khoury J, Sauerbeck L, Salisbury S et al. Natural history of perihematomal edema in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002;33:2631-5.
18. Gebel JM Jr, Jauch EC, Brott TG, Khoury J, Sauerbeck L, Salisbury S et al. Relative edema volume is a predictor of outcome in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke2002;33:2636-41.
19. Sangha N, Gonzales NR. Treatment targets in Intracerebral hemorrhage. Neurotherapeutics 2011;8:374387.
20. Ferro JM. Update on intracerebral hemorrhage. J Neurol 2006;253:985-99.
21. Silva Y, Leiria R, Tejada J, Lainez JM, Castillo J, Davalos A. Stroke Project Cerebrovascular Diseases Group of the Spanish Neurological Society Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke 2005;36:86-91.
22. Butcher KS, Baird T, Macgregor L, Desmond P, Tress B, David S. Periematomal edema in primary ICH is plasma derived. Stroke 2004;35:1879-85.
23. Kidwell CS, Chalela JA, Saver JL, Starkman S, Hill MD, Demchuk AM et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004;292:1823-30.
24. Zaheer A, Ozsunar Y, Schefer PW. Magnetic resonance imaging of cerebral hemorrhagic stroke. Top Magn Reson Imaging 2000;11:288-99.
25. Kidwell CS, Wintermark M. Imaging of intracranial hemorrhage. Lancet Neurol 2008;7:256-67.
26. Kidwell CS, Saver JL, Mattiello J, Warach S, Liebeskind DS, Starkman S et al. Diffusion-perfusion MR evaluation of perihematomal injury in hyperacute intracerebral hemorrhage. Neurology 2001;57:1611-7.
27. Wiszniewska M, Devuyst G, Bogousslavsky J, Ghika J, Van Melle G. What is the significance of leukoaraiosis in patients with acute ischemic stroke? Arch Neurol 2000;57:967-73.
28. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging, 2009;3:337-52.
29. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010;341:c3666.
30. Palumbo V, Boulanger JM, Hill MD, Inzitari D, Buchan AM; CASES Investigators. Leukoaraiosis and ICH after thrombolysis in acute stroke. Neurology 2007;68:1020-4.
31. Lou M, Al-Hazzani A, Goddeau RP Jr, Novak V, Selim M. Relationship between white-matter hyperintensities and hematoma volume and growth in patients with intracerebral hemorrhage. Stroke 2010;41:34-40.
32. Neumann-Hefelin T, Helig S, Berkefeld J, Fiehler J, Gass A, Humpich M et al. MR Stroke Group. Leukoaraiosis is a risk factor for symptomatic ICH after thrombolysis for acute stroke. Stroke 2006;37:2463-6.
33. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999;53:1319-27.
34. Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 2002;59:193-7.
35. Park JH, Park SW, Kang SH, Nam TK, Min BK, Hwang SN. Detection of traumatic cerebral microbleeds by susceptibility-weighted image of MRI. J Korean Neurosurg Soc 2009;46:365-9.
36. *-weighted magnetic resonance imaging data from 570 patients. Stroke 2007;38:2738-44.
37. Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CL et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke 2010;41:1222-8.
38. Cordonnier C. Brain microbleeds: more evidence, but still a clinical dilemma. Curr Opin Neurol 2011;24:69-74.
39. Greenberg SM, Eng JA, Ning M, Smith EE, Rosand J. Hemorrhage burden predicts recurrent ICH after lobar hemorrhage. Stroke 2004;35:1415-20.
40. Maxwell SS, Jackson CA, Paternoster L, Cordonnier C, Thijs V, Al-Shahi Salman R et al. Sudlow CL. Genetic associations with brain microbleeds: Systematic review and meta-analyses. Neurology 2011;77:158-67.
41. Labauge P, Denier C, Bergametti F, Toumier-Lasserve E. Genetics of cavernous angiomas. Lancet Neurol 2007;6:237-44.
42. McDonald J, Bayrak-Toydemir P, Pyeritz RE. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med 2011;13:607-16.
43. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001;56:537-9.
44. Biffi A, Anderson CD, Jagiella JM, Schmidt H, Kissela B, Hansen BM et al. International Stroke Genetics Consortium. APE genotype and extent of bleeding and outcome in lobar intracerebral hemorrhage: a genetic association study. Lancet Neurol 2011;10:702-9.
45. Revesz T, Holton JL, Lashley T, Plant G, Frangione B, Rostagno A et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol 2009 118:115-30.
46. Natté R, Maat-Schieman ML, Haan J, Bornebrek M, Roos RA, Van Duinen SG. Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. Ann Neurol 2001;50:765-72.
47. Maat-Schieman ML, Van Duinen SG, Bornebrek M, Haan J, Roos RA. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): II-A review of histopathological aspects. Brain Pathol 1996;6:115-20.
48. Zhang-Nunes SX, Maat-Schieman ML, Van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol 2006;16:30-9.
49. Cohen DH, Feiner H, Jensson O, Frangione B. Amyloid fibril in hereditary cerebral hemorrhage with amyloidosis (HCHWA) is related to the gastrentero-pancreatic neurendocrine protein, gamma trace. J Exp Med 1983;158:623-8.
50. Jensson O, Gudmundsson G, Arnason A, Blöndal H, Petursdottir I, Thorsteinsson L et al. Hereditary cystatin C (gamma-trace) amyloid angiopathy of the CNS causing cerebral hemorrhage. Acta Neurol Scand 1987;76:102-14.
51. Levy E, Jaskolski M, Grubb A. The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol 2006;16:60-70.
52. Calero M, Pawlik M, Soto C, Castaño EM, Sigurdsson EM, Kumar A et al. Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. J Neurochem 2001;77:628-37.
53. Frangione B, Révész T, Vidal R, Holton J, Lashley T, Houlden H et al. Familial cerebral amyloid angiopathy related to stroke and dementia. Amyloid 2001;8(Suppl l):36-42.
54. Hund E, Linke RP, Willig F, Grau A. Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment. Neurology 2001;56:431-5.
55. Hagiwara K, Ochi H, Suzuki S, Shimizu Y, Tokuda T, Murai H et al. Highly selective leptomeningeal amyloidosis with transthyretin variant Ala25Thr. Neurology 2009;72:1358-60.
56. Goren H, Steinberg MC, Farboody GH. Familial oculoleptomeningeal amyloidosis. Brain. 1980;103:473-95.
57. Gupta MC, Graham PL, Kramer JM. Characterization of alpha 1 (IV) collagen mutations in Cenorhabditis elegans and the effects of alpha 1 and alpha2 (IV) mutations on type IV collagen distribution. J Cell Biol 1997;137:1185-96.
58. Solomon E, Hioms LR, Spurr N, Kurkinen M, Barlow D, Hogan BL et al. Chromosomal assignments of the genes coding for human types II, III, and IV collagen: a dispersed gene family. Proc Natl Acad Sei U S A 1985;82:3330-4.
59. Emanuel BS, Sellinger BT, Gudas LJ, Myers JC. Localization of the human procollagen alpha-1 (IV) gene to chromosome 13q34 by in situ hybridization. Am J Hum Genet 1986;38:38-44.
60. Bilguvar K, Di Luna ML, Bizzarre MJ, Bayri Y, Schneider KC, Lifton RP et al Pacifier and Breastfeeding Trial Group. CO-L4A1 mutation in preterm intraventricular hemorrhage. J Pediatr 2009;155:743-5.
61. Gould DB, Phalan FC, Breedveld GJ, Van Mil SE, Smith RS, Schimenti JC et al. Mutations in Col4al cause perinatal cerebral hemorrhage and porencephaly. Science 2005;308:1167-71.
62. Lanfranconi S, Markus HS. COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review. Stroke 2010;41:e513-8.
63. Vahedi K, Massin P, Guichard JP, Miocque S, Polivka M, Goutieres F et al. Hereditary infantile hemiparesis, retinal arteriolar tortuosity, and leukencephalopathy. Neurology 2003;60:57-63.
64. Plaisier E, Gribouval O, Alamowitch S, Mougenot B, Prost C, Verpönt MC et al. COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. N Engl J Med 2007;357:2687-95.
65. Weng YC, Sonni A, Labelle-Dumais C, De Leau M, Kauffman WB et al. COL4A1 mutations in patients with sporadic late-onset intracerebral hemorrhage. Ann Neurol 2012;71:470-7.
66. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P et al. Notch3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia. Ann NY Acad Sei 1997;826:213-7.
67. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707-10.
68. Chabriat H, Joutel A, Dichgans M, Toumier-Lasserve E, Bousser MG. Cadasil. Lancet Neurol 2009;8:643-53.
69. Domenga V, Fardoux P, Lacombe P, Monet M, Maciazek J, Krebs LT et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev 2004;18:2730-5.
70. Belin De Chantemele EJ, Retailleau K, Pinaud F, Vessieres E, Bocquet A et al. Notch3 is a major re.g.ulator of vascular tone in cerebral and tail resistance arteries. Arterioscler Thromb Vase Biol 2008;28:2216-24.
71. Joutel A, Monet-Lepretre M, Gosele C, Baron-Menguy C, Hammet A, Schmidt S et al. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J Clin Invest 2010;120:433-45.
72. Singhal S, Rich P, Markus HS. The spatial distribution of MR imaging abnormalities in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukencephalopathy and their relationship to age and clinical features. AJNR Am J Neuroradiol 2005;26:2481-7.
73. Jacqmin M, Hervé D, Viswanathan A, Guichard JP, During M, Dichgans M, Chabriat H. Confluent thalamic hyperintensities in CADASIL. Cerebrovasc Dis 2010;30:308-13.
74. Hervé D, Godin O, Dufouil C, Viswanathan A, Jouvent E, Pachai C et al. Three-dimensional MRI analysis of individual volume of Lacunes in CADASIL. Stroke 2009;40:124-8.
75. Pantoni L, Pescini F, Nannucci S, Sarti C, Bianchi S, Dotti MT et al. Comparison of clinical, familial, and MRI features of CADASIL and NOTCH3-negative patients. Neurology 2010;74:57-63.
76. Hassan A, Markus HS. Genetics and ischemic stroke. Brain 123:1784-1812.
77. Markus H 2004. Genes for stroke. J Neurol Neurosurg Psychiatry 2000;75:1229-31.
78. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes: a family history study. Stroke 2003;34:1364-9.
79. Hallman DM, Berwinkle E, Saha N, Sandholzer C, Menzel HJ, Csâzâr A et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 1991;49:338-49.
80. Greenberg SM, Briggs ME, Hymann BT, Kokoris GJ, Takis C, Kanter DS et al. Apoliprotein E e4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 1996;27:1333-7.
81. Yamada M, Itoh Y, Suematsu N, Matsushita M, Otomo E. Lack of an association between apolipoprotein E e4 and cerebral amyloid angiopathy in elderly Japanese. Ann Neurol 1996;39:683.
82. Nicoll JA, Burnett C, Love S, Graham DI, Dewar D, Ironside JW et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 1997;41:716-21.
83. Garcia C, Pinhoe Melo T, Rocha L, Lechner MC. Cerebral hemorrhage and ape. J Neurol 1999;246:830-4.
84. O'Donnell HC, Rosand J, Knudsen KA, Furie KL, Segal AZ, Chiu RI et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000;342:240-5.
85. Greenberg SM, Vonsattel JP, Segal AZ, Chiu RI, Clatworthy E, Liao A et al. Association of apolipoprotein E e and vasculopathy in cerebral amyloid angiopathy. Neurology 1998;50:961-5.
86. Nicoll JA, McCarron MO. APE gene polymorphism as a risk factor for cerebral amyloid angiopathy-related hemorrhage. Amyloid 2001;8(Suppl 1):51-5.
87. Tzourio C, Arima H, Harrap S, Anderson C, Godin O, Woodward M et al. APE genotype, ethnicity, and the risk of cerebral hemorrhage. Neurology 2008;70:1322-8.
88. Sudlow C, Martínez González NA, Kim J, Clark C. Des apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analyses of 31 studies among 5961 cases and 17, 965 controls. Stroke 2006;37:364-70.
89. Peck G, Smeeth L, Whittaker J, Casas JP, Hingorani A, Sharma P. The genetics of primary hemorrhagic stroke, subarachnoid hemorrhage and ruptured intracranial aneurysms in adults. PLoS One 2008;3:e3691.
90. Biffi A, Sonni A, Anderson CD, Kissela B, Jagiella JM, Schmidt H et al. Variants at APE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol 2010;68:934-43.
91. Biffi A, Anderson CD, Jagiella JM, Schmidt H, Kissela B, Hansen BM et al. International Stroke Genetics Consortium. APE genotype and extent of bleeding and outcome in lobar intracerebral hemorrhage: agenetic association study. Lancet Neurol 2011;10:702-9.
92. Lemmens R, Gorner A, Schrooten M, Thijs V. Association of Apolipoprotein E ε2 with whte matter disease but not with microbleeds. Stroke 2007;38:1185-8.
93. De Leeuw FE, Richard F, De Groot JC, Van Duijn CM, Hofman A, Van Gijn J et al. Interaction between hypertension, ape, and cerebral white matter lesions. Stroke 2004;35:1057-60.
94. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 2000;55:947-51.
95. Niu T, Chen X, Xu X. Angiotensin-converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications. Drugs 2002;62:977-993.
96. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin 11-mediated cardiovascular and renal diseases. Pharmacol Rev 2000;52:11-34.
97. Slowik A, Turaj W, Dziedzic T, Hefele A, Pera J, Malecki MT et al. DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. Neurology 2004;63:359-61.
98. Nakata Y, Katsuya T, Rakugi H, Takami S, Sato N, Kamide K et al. Polymorphism of angiotensin converting enzyme, angiotensinogen, and apolipoprotein E genes in a Japanese population with cerebrovascular disease. Am J Hypertens 1997;10:1391-5.
99. Lin JJ, Yueh KC, Lin GY, Chang DC, Chang CY, Shieh HL et al. Lack of association between angiotensin I-converting enzyme gene deletion polymorphismnd cerebrovascular disease in Taiwanese. J Formos Med Assoc 2000;99:895-901.
100. Kalita J, Misra UK, Bindu IS, Kumar B, Mittal B. Angiotensinconverting enzyme (rs4646994) and a ADDUCIN (rs4961) gene polymorphisms' study in primary spontaneous intracerebral hemorrhage. Neurol India 2011;59:41-6.
101. Corral J, Iniesta JA, Gonzalez-Conejero R, Villalon M, Vicente V. Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. Blood 2001;97:2979-82.
102. Catto AJ, Kohler HP, Bannan S, Stickland MH, Carter A, Grant PJ. Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage. Stroke 1998;29:813-6.
103. Gemmati D, Serino ML, Ongaro A, Tognazzo S, Moratelli S, Resca R et al. A common mutation in the gene for coagulation factor XIII-A (VAL34Leu): a risk factor for primary ICH is protective against atherothrombotic diseases. Am J Hematol 2001;67:183-8.
104. Slowik A, Dziedzic T, Pera J, Figlewicz DA, Szczudlik A. Coagulation factor XIII VaI34Leu polymorphism in patients with small vessel disease or primary intracerebral hemorrhage. Cerebrovasc Dis 2001;19:165-170.
105. Vila N, Obach V, Revilla M, Oliva R, Chamorro A. Alpha (l)-antichymotrypsin gene polymorphism in patients with stroke. Stroke 2000;31:2103-5.
106. Obach V, Revilla M, Vila N, Cervera AA, Chamorro A. A alpha (1) - antichymotrypsin polymorphism: a risk factor for hemorrhagic stroke in normotensive subjects. Stroke 2001;32:2588-91.
107. Pera J, Slowik A, Dziedzic T, Szczudlik A. SERPINA3 polymorphism is not associated with primary ICH in a Polish population. Stroke 2006;37:906-7.
108. Li Z, Sun L, Zhang H, Liao Y, Wang D, Zhao B et al. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a Multicenter Case-Control Study in China. Stroke Sep. 2003;34:2085-90.
109. Fang X, Namba H, Akamine S, Sugiyama K. Methylenetetrahydrofolate reductase gene polymorphisms in patients with cerebral hemorrhage. Neurol Res 2005;27:73-6.
110. Somarajan BI, Kalita J, Mittal B, Misra UK. Evaluation of MTH-FR C677T polymorphism in ischemic and hemorrhagic stroke patients. A case-control study in a Northern Indian population. J Neurol Sci 2011 304:67-70.
111. Hultdin J, Van Guelpen B, Winkvist A, Hallmans G, Weinehall L, Stegmayr B, Nilsson TK. Prospective study of first stroke in relation to plasma homocysteine and MTHFR 677C>T and 1298A>C genotypes and haplotypes - evidence for an association with hemorrhagic stroke. Clin Chem Lab Med 2011;49:1555-62.
112. Alberts MJ, Davis JP, Graffagnino C, McClenny C, Delong D, Granger C et al. Endoglin gene polymorphism as a risk factor for sporadic intracerebral hemorrhage. Ann Neurol 1997 41:683-6.
113. Iniesta JA, Corral J, Gonzalez-Conejero R, Piqueras C, Vicente V. Polymorphisms of platelet adhesive receptors: do they play a role in primary intracerebral hemorrhage? Cerebrovasc Dis 2003;51-5.
114. Carter AM, Catto AJ, Bamford JM, Grant PJ. Platelet GP Ilia P1A and GP lb variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Thromb Vase Biol 1998;18:1124-31.
115. Iniesta JA, Gonzalez-Conejero R, Piqueras C, Vicente V, Corral J. Platelet GP Ilia polymorphism HPA-1 (P1A) protects against subarachnoid hemorrhage. Stroke 2004;35:2282-6.
116. Song W, Chen J, Sun K, Yu H, Hui R. No association of PLIN polymorphisms with hemorrhagic and ischemic stroke. Stroke 2008;39:470-2.
117. Dasu MR, Barrow RE, Spies M, Herndon DN. Matrix metalloproteinase expression in cytokine stimulated human dermal fibroblasts. Bums 2003;29:527.
118. Tuttolomondo A, Di Raimondo D, Di Sciacca R, Pinto A, Licata G. Inflammatory cytokines in acute ischemic stroke. Current Pharmaceutical Design 2008;14:3574.
119. Um JY, Kim HM. Polymorphisms of RANTES and IL-4 genes in cerebral infarction. J Mol Neurosci 2009;37:1.
120. James ML, Warner DS, Laskowitz DT. Preclinical models of intracerebral hemorrhage: a translational perspective. Neurocritical Care 2007;9:139.
121. Chen YC, Hu FJ, Chen P, Wu YR, Wu HC, Chen ST et al. Association of TNF-alpha gene with spontaneous deep ICH in the Taiwan population: a case control study. BMC Neurol 2010;10:41.
122. Chomarat P, Vannier E, Dechanet J, Rissoan MC, Banchereau J, Dinarello CA et al. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995;154:1432-9.
123. Park HJ, Kim MJ, Kang W, Kim SK, Lee JS, Park HK Y et al. Association between interleukin-4 gene polymorphisms and ICH in Korean population. Int J Immunogenet 2011;38:321-5.
124. Rockman MV, Hahn MW, Soranzo N, Goldstein DB, Wray GA. Positive selection on a human-specific transcription factor binding site regulating IL4 expression. Current Biology 2003;13:2118.
125. Chao CC, Molitor TW, Hu S. Neuroprotective role of IL-4 against activated microglia. J Immunol 1993;151:1473.
126. Chao CC, Hu S, Peterson PK. Modulation of human microglial cell superoxide production by cytokines. J Leukocyte Biol 1995;58:65.
127. Lovett-Racke E, Smith ME, Arredondo LR, Bittner PS, Ratts RB, Shive CL et al. Developmental regulated gene expression of Th2 cytokines in the brain. Brain Res 2000;870:27-35.
128. Yamada Y, Metoki N, Yoshida H, Satoh K, Ichihara S, Kato K et al. Genetic risk for ischemic and hemorrhagic stroke. Arterioscler Thromb Vase Biol 2006;26:1920-5.
129. Pawlikowska L, Tran MN, Achrol AS, McCulloch CE, Ha C, Lind DL et al. UCSF BAVM Study Project. Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations. Stroke 2004;35:2294-300.
130. Silva Y, Leira R, Tejada J, Lainez JM, Castillo J, Davalos A. Stroke Project, Cerebrovascular Diseases Group of the Spanish Neurological Society. Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke 2005;36:86-91.
131. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 2002;39:279-91.
132. Dasu MR, Barrow RE, Spies M, Hemdon DN. Matrix metalloproteinase expression in cytokine stimulated human dermal fibroblasts. Bums 2003;29:527-31.
133. Kim DH, Ahn WY, Kim DK, Che BK, Kim SK, Jo DJ et al. A Promoter polymorphism (rs 17222919, -1316T/G) of ALOX5AP is associated with ICH in Korean population. Prostaglandins Leukot Essent Fatty Acids 2011;85:115-20.
134. Appelboom G, Piazza M, Hwang BY, Bruce S, Smith S, Bratt A et al. Complement Factor H Y402H polymorphism is associated with an increased risk of mortality after intracerebral hemorrhage. J Clin Neurosci 2011;18:1439-43.
135. Bai Y, Chen J, Sun K, Wang Y, Hui R. A functional variant in promoter re.g.ion of platelet-derived growth factor-D is probably associated with intracerebral hemorrhage. J Neuroinfiammation 2012;30:26.
136. Gomez-Sanchez JC, Delgado-Esteban M, Rodriguez-Hemandez I, Sobrino T, Perez De La Ossa N, Reverte S et al. The human Tp53 Arg72Pro polymorphism explains different functional prognosis in stroke. J Exp Med 2011;208:429-37.
137. Viswanathan A, Rakich SM, Engel C, Snider R, Rosand J, Greenberg SM et al. Antiplatelet use after intracerebral hemorrhage. Neurology; 2006;66:206-9.
138. Navarro-Núñez L, Lozano ML, Rivera J, Corral J, Roldán V, González-Conejero R et al. The association of the beta 1-tubulin Q43P polymorphism with ICH in men. Hematologica 2007;92:513-8.
139. Biffi A, Shulman JM, Jagiella JM, Cortellini L, Ayres AM, Schwab K et al. Genetic variation at CR1 increases risk of cerebral amyloid angiopathy. Neurology 2012;78:334-41.
140. Bersano A, Ballabio E, Bresolin N, Candelise L. Genetic polymorphisms for the study of multifactorial stroke. Hum Mutat 2008;29:776-95.